 |
|
Drug fends off kidney cancer progression
May 19, 2008New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments. The study was led by Robert Motzer, MD, an attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), who will present the findings on May 31 at the annual meeting of the American Society for Clinical Oncology.
"This study has given us a new and clearly useful tool for treating renal cell tumors, and everolimus is an important step forward in terms of disease management and quality of life for patients living with this disease," said Dr. Motzer.
Kidney cancer is among the ten most common cancers in both men and women. The American Cancer Society estimates that there will be about 54,390 new cases of kidney cancer diagnosed in the US in 2008, and that about 13,010 people will die from the disease.
Everolimus, a once-daily oral therapy, targets the mTOR protein, which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth. It is currently being evaluated for the treatment of several other cancers including lymphoma and neuroendocrine tumors.
More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had disease that had not progressed, compared to only 2 percent of the placebo group. The average difference in progression free survival was four months for everolimus, compared to 1.9 months for the placebo group.
In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed researchers to offer everolimus to the patients receiving placebo.
"For almost 20 years, we made no headway in the management of advanced kidney cancer," notes Dr. Motzer. "Recently, the identification of several new angiogenesis- targeted agents has provided us with new treatment options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, everolimus could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of treatment advances."
Everolimus was well tolerated by patients and the most common side effects were mouth ulcers, anemia, skin rash and weakness.
Memorial Sloan-Kettering Cancer Center
Everolimus, a once-daily oral therapy, targets the mTOR protein, which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth. It is currently being evaluated for the treatment of several other cancers including lymphoma and neuroendocrine tumors.
More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had disease that had not progressed, compared to only 2 percent of the placebo group. The average difference in progression free survival was four months for everolimus, compared to 1.9 months for the placebo group.
In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed researchers to offer everolimus to the patients receiving placebo.
"For almost 20 years, we made no headway in the management of advanced kidney cancer," notes Dr. Motzer. "Recently, the identification of several new angiogenesis- targeted agents has provided us with new treatment options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, everolimus could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of treatment advances."
Everolimus was well tolerated by patients and the most common side effects were mouth ulcers, anemia, skin rash and weakness.
Memorial Sloan-Kettering Cancer Center
Kidney Cancer Current Events and Kidney Cancer News RSSResearch suggests doctors should consider kidney-sparing surgery
A study of almost 1,500 kidney cancer patients treated at Memorial Sloan Kettering Cancer Center suggests that surgery to spare as much kidney tissue as possible may improve overall survival in patients who also have reduced kidney function at the time their cancer is diagnosed.
State's first single incision robotic kidney removal
For the first time in Michigan, a diseased kidney has been surgically removed at Henry Ford Hospital using highly sophisticated 3D robotics through a single incision.
American Cancer Society study finds high use of complementary methods among cancer survivors
A new study from researchers at the American Cancer Society finds many cancer patients use complementary and alternative methods, most often prayer, relaxation, supplements, meditation, and massage.
NewYork-Presbyterian/Columbia leads research into robotic surgery for kidney cancer
Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is helping bring the advantages of robotic surgery, including reduced pain and quicker recovery, to kidney cancer patients.
New study finds advanced liver cancer patients live longer by taking anti-cancer drug sorafenib
Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug.
Majority of kidney cancers diagnosed at earliest stage
Patients in the United States today are now much more likely to be diagnosed with smaller tumors, in the earliest, most treatable stage of kidney cancer than a decade ago, leading to a slightly higher survival rate, according to the results of a national study led by a UC San Diego Medical Center researcher.
Overweight and obesity cause 6,000 cancers a year in UK women
The study shows that overweight and obese women in the UK are at a higher risk of developing and dying from cancer. In fact, the researchers estimate that 5% of all cancers (about 6,000 annually) are attributable to being overweight or obese.
Study shows blood markers can help choose best dose for antiangiogenic drugs
Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.
Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
Surgeons specializing in laparoscopic procedures at UT Southwestern Medical Center have successfully removed a patient's kidney by performing a unique nephrectomy entirely through the belly button.
First biomarker discovered that predicts prostate cancer outcome
Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery.
More Kidney Cancer Current Events and Kidney Cancer News Articles
 | 100 Questions & Answers About Kidney Cancer (100 Questions & Answers about . . .) by Steven C. Campbell There are 37,000 cases of kidney (renal cell) cancer in the US and 13,000 related deaths annually. 100 Questions and Answers About Kidney Cancer explains all aspects of the disease resulting in full awareness of what to expect when battling kidney... |
 | Imaging of Kidney Cancer (Medical Radiology / Diagnostic Imaging) This is one of the first books to deal specifically with diagnostic imaging of the entire spectrum of kidney cancers. Both new and conventional imaging modalities are fully considered. After an introductory chapter on the histopathological classification of kidney cancers, the advantages and disadvantages of the various imaging modalities used in the diagnosis and assessment of disease extension... |
 | Carcinoma of the Kidney (Contemporary Issues in Cancer Imaging) The last two decades have seen ground-shifting changes in the epidemiology, genetics, diagnosis and management of renal cancer. Advances in diagnosis have led to many tumours being identified at an asymptomatic stage. There have also been parallel advances in treatment, such as nephron sparing procedures and radiologically guided ablative procedures. However, these changes have brought with them... |
 | Dx/ Rx: Genitourinary Oncology: Cancer of the Kidney, Bladder, and Testis (Dx/Rx Oncology) by Matthew Galsky Designed for both oncologists and urologists, Dx/Rx: Genitourinary Oncology is a current, concise, quick reference guide to the diagnosis and therapy of cancers of the bladder/urothelial tract, kidneys, and testis. Tightly organized into a super-condensed outline-bulleted format, this handy, pocket-sized manual details precise, up-to-date information on the epidemiology, classification,... |
 | Kidney Cancer (Cancer Treatment and Research) Kidney cancer is a heterogenous disease. This book covers: -new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques; -new staging and prognostic capabilities; -evolving therapeutic options include, cell based vaccine, gene and antibody therapy; -molecular genetics allow for a better understanding of the various types of kidney... |
 | So They Tell Me: Surviving Kidney Cancer and a Stroke by Trevor Measday, Lesley Measday How many people prepare for one traumatic experience in their lifetime and the possible lifestyle changes they may have to live with? This book describes two such experiences in a matter of weeks suffered by a couple who were in their early fifties, with two sons who were making their way in the world. An opportunity to set up home in the south west of England had occurred three years earlier.... |
 | Cancer and the Kidney Cancer and the Kidney addresses the interface and overlap of nephrology and oncology. Kidney disease, metabolic disturbances or kidney failure can occur in a cancer patient, and cancers may complicate the lives of dialysis or transplant patients. These cross-specialty clinical problems and their management are the focus of this book, which provides nephrologists and oncologists with an accurate... |
 | 21st Century Complete Medical Guide to Kidney Cancer (Renal Cell, Transitional Cell, Wilm¿s Tumor): Authoritative Government Documents and Clinical References for Patients and Physicians with Practical Information on Diagnosis and Treatment Options by PM Medical Health News This up-to-date and comprehensive CD-ROM provides a superb collection of official Federal government documents on kidney cancer: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered. There is no other reference that is as fast, convenient, and portable - everything you need to know, from the... |
| Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News by Jeff Evans This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... | |
 | Kidney Cancer - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and... |
| © 2008 BrightSurf.com |